"Peptides while breastfeeding" has two very different answers depending on what is meant by "peptides". Approved peptide medicines have labels, and every modern US label has a section on lactation that says what is known. Research peptides sold online have no label and, as this page documents, no study. This page reads the labels, counts the database records, and states the absence where that is the finding.
It does not say any peptide is safe or unsafe to use while breastfeeding. What has been studied, what has not, and who has written what — then the decision goes to the prescriber and the baby's doctor. GLP-1 medicines such as semaglutide and tirzepatide are covered by GLP1 Ledger's GLP-1 and breastfeeding page and are not repeated here.
What 13 approved labels say
We read the lactation section (8.2, or "Nursing Mothers" on older labels) of each product's current US label through openFDA on 15 October 2026.
| Medicine (brand on the label read) | Label date | What the label says about breastfeeding |
|---|---|---|
| Tesamorelin (Egrifta SV) | 2026-07-29 | No data on milk, infant or milk supply; because of HIV transmission risk and possible adverse effects, mothers should not breastfeed |
| Teriparatide | 2025-05-27 | Not known whether excreted in milk; avoid use in women who are breastfeeding |
| Cetrorelix | 2025-06-12 | Not known whether excreted; should not be used by nursing mothers |
| Ganirelix | 2025-02-20 | Should not be used by lactating women; not known whether excreted |
| Leuprolide (Vabrinty) | 2026-04-30 | No information; decide whether to stop breastfeeding or stop the drug |
| Bremelanotide (Vyleesi) | 2025-11-13 | No information on milk, infant or milk supply; weigh benefits of breastfeeding against the mother's need |
| Abaloparatide (Tymlos) | 2026-08-11 | Not indicated for women who can become pregnant; no information on milk |
| Octreotide | 2025-01-16 | No human information; in rats, milk levels were about 1% of plasma (ratio 0.009) |
| Calcitonin salmon (injection) | 2026-03-06 | No information; calcitonin inhibited lactation in rats |
| Vasopressin | 2025-02-15 | No data in human or animal milk |
| Chorionic gonadotropin (hCG) | 2025-04-11 | Not known whether excreted; caution advised |
| Desmopressin | 2025-11-13 | One study in postpartum women: little if any change in desmopressin in milk after a 0.01 mg nasal dose, despite a marked change in plasma |
| Oxytocin (Pitocin) | 2026-05-06 | No lactation section; notes that oxytocin's 1–6 minute half-life is shorter during lactation |
Read across the table: one label carries a human milk measurement (desmopressin), one carries an animal milk ratio (octreotide), and eleven have no milk data at all. Five tell readers not to combine the drug with breastfeeding or to choose between them. The "no information" labels are not reassurance; they record that the question was not studied before approval.
Oxytocin is the special case. It is the body's own milk-ejection hormone and is given around birth, so a nursing infant is already exposed to the mother's own oxytocin. The Pitocin label covers labour and postpartum bleeding and says nothing about breastfeeding beyond the half-life note.
What the lactation database holds
LactMed, run by the US National Library of Medicine, is the standard reference clinicians use for drugs in breastfeeding. A title search of its records through NCBI's search service on 15 October 2026 found:
- A record: oxytocin, desmopressin, octreotide, teriparatide, bremelanotide, calcitonin, vasopressin, somatropin (growth hormone).
- No record found by title: tesamorelin, abaloparatide, leuprolide, cetrorelix, ganirelix, hCG — and every research peptide searched: BPC-157, TB-500 or thymosin beta-4, sermorelin, ipamorelin, kisspeptin, melanotan, GHK-Cu, glutathione, NAD.
The record pages themselves sit behind a browser check that automated reading cannot pass, so this page reports which records exist, not what each says. A clinician or a parent can open them directly at the LactMed home page.
The research peptides: the documented absence
For the peptides sold online as research chemicals, there is no label to read and no database record. We also searched PubMed on 15 October 2026 for each name combined with lactation, breastfeeding, breast milk or human milk:
| Compound | PubMed records | What they are |
|---|---|---|
| BPC-157 | 0 | — |
| TB-500 / thymosin beta-4 | 0 | — |
| Ipamorelin | 0 | — |
| CJC-1295 | 0 | — |
| Epitalon | 0 | — |
| GHK-Cu / copper peptide | 0 | — |
| Selank, semax | 0 | — |
| Tesamorelin | 0 | — |
| MOTS-c | 1 | A mouse study of maternal obesity |
| Melanotan | 2 | Sheep and rat appetite physiology |
| Sermorelin | 4 | Milk yield in dairy cows and sows (1984–1988) |
| Kisspeptin | 82 (19 tagged human) | How breastfeeding suppresses kisspeptin signalling and fertility — physiology, not taking kisspeptin |
Not one of these records describes a breastfeeding woman taking the compound. The sermorelin records are a reminder of how far the literature is from the question: growth-hormone-releasing factor was studied as a way to raise milk yield in livestock in the 1980s. The kisspeptin records describe the body's own hormone; our kisspeptin for women page covers the trials that gave it as a drug, none in breastfeeding women.
What this absence means is narrow and should be read exactly: nobody has measured whether these compounds reach milk, what they do to an infant, or whether they change milk supply. It is not evidence of harm and not evidence of safety. On top of the missing data sit the known problems with research-grade vials themselves — unverified content and sterility — set out on our are peptides safe page.
The one milk study that has finished
ClinicalTrials.gov lists a phase 4 study of Vyleesi in breastfeeding women (NCT06867835), sponsored by Cosette Pharmaceuticals: 10 healthy women, 10 days to six months after giving birth, one 1.75 mg dose, milk collected over 24 hours to measure bremelanotide concentration and total exposure. Participants pumped and stored milk in advance and stopped breastfeeding for the study period. It started in July 2025 and reached primary completion on 15 November 2025.
As of 15 October 2026 it had posted no results, and the Vyleesi label dated 13 November 2025 still states there is no information on bremelanotide in human milk. When the results appear, bremelanotide will be the first peptide in this table with a measured milk level in women since desmopressin. What the trials found in women generally is on our PT-141 for women page.
Pregnancy, briefly
Breastfeeding questions often come with pregnancy questions. Two label positions from the table's products are worth stating: tesamorelin is contraindicated in pregnancy (Egrifta SV label, 2026-07-29), and Vyleesi's label says use during pregnancy is not recommended and advises contraception. No research peptide has any human pregnancy data; our BPC-157 side effects page notes that its one rat reproductive study did not cover the full reproductive cycle.
Where the decision goes
- The prescriber, for any approved peptide medicine — the label sections above are written for them.
- The infant's doctor or a lactation specialist, who can weigh the infant's age, health and feeding.
- LactMed, for the records that exist.
For the related question of how long these compounds stay in the body, see our peptide half-life page. Other everyday-exposure questions — alcohol, for example — are on our peptides and alcohol page.
Sources and dates
Read 15 October 2026: openFDA drug-label records (lactation or nursing-mothers sections; contraindications for Egrifta SV) for tesamorelin (Egrifta SV), teriparatide, cetrorelix, ganirelix, leuprolide (Vabrinty), bremelanotide (Vyleesi), abaloparatide (Tymlos), octreotide, calcitonin salmon, vasopressin, chorionic gonadotropin, desmopressin and oxytocin (Pitocin), each at the effective date shown; NCBI Bookshelf title search of LactMed records; PubMed searches as listed, with record summaries for the sermorelin, MOTS-c, melanotan and kisspeptin results; ClinicalTrials.gov record NCT06867835.